AN2 Therapeutics (ANTX)
Develops boron-chemistry medicines for hematologic disease, infectious disease, and oncology.
$6.30
Pre-market+0.36 (+6.06%)
At close$5.94(+8.39%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions52 holders · as of Mar 31, 2026 | 58.02% | 21.89M shares | |
| Insiders13 holders · as of Sep 2, 2026 | 17.35% | 6.55M shares | |
| Strategic holders2 holders · as of Mar 13, 2026 | 10.95% | 4.13M shares | |
| Otherremainder | 13.68% | 5.16M shares |
37.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
52 holders · 21.89M shares · 25 new positions · 38 increased · 8 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vivo Capital, LLC | 3.15M | 8.36% | +3.15Mnew | May 20, 2026 |
| Commodore Capital LP | 2.33M | 6.18% | +2.33Mnew | May 15, 2026 |
| Millennium Management LLC | 2.22M | 5.89% | +2.13M | May 15, 2026 |
| Spruce Street Capital LP | 1.66M | 4.40% | +1.66Mnew | May 14, 2026 |
| Almitas Capital LLC | 1.48M | 3.92% | 0 | May 15, 2026 |
| Vanguard Capital Management LLC | 1.01M | 2.68% | +1.01Mnew | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 1.00M | 2.65% | +1.00Mnew | May 15, 2026 |
| Woodline Partners LP | 993.7K | 2.63% | +847.7K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BML Investment Partners, L.P. | 19.20% | 5.75M | 13G | Feb 13, 2025 ↗ |
| Commodore Capital LP | 9.90% | 3.70M | 13G | Mar 16, 2026 ↗ |
| Coastlands Capital LP | 9.30% | 2.82M | 13G | Jun 4, 2025 ↗ |
| Vivo Opportunity Fund Holdings, L.P. | 8.00% | 2.86M | 13G | Mar 13, 2026 ↗ |
| Eric Easom | 7.90% | 2.23M | 13G | Feb 13, 2026 ↗ |
| Adjuvant Global Health Technology Fund, L.P. | 6.70% | 2.00M | 13G | Feb 28, 2025 ↗ |
| Integrated Core Strategies (US) LLC | 6.00% | 2.14M | 13G | Mar 13, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | Margaret M. FitzPatrickdirector | Purchase | 2,098 | $5.53 | 10,708 |
| Aug 17, 2026 | Robin Shane Readnourdirector | Sale · 2 lots | 35,402 | $6.01 | 565,592 |
| Jul 8, 2026 | Joshua M. Eizenofficer: See Remarks | Sale | 5,945 | $4.17 | 206,554 |
| May 29, 2026 | Sarah Joanne Williamsofficer: Principal Accounting Officer | Sale | 265 | $4.43 | 66,583 |
| Mar 3, 2026 | Sarah Joanne Williamsofficer: Principal Accounting Officer | Sale | 327 | $1.06 | 66,848 |
| Jan 6, 2026 | Joshua M. Eizenofficer: See Remarks | Sale | 6,931 | $1.01 | 152,499 |
| Jan 5, 2026 | Joshua M. Eizenofficer: See Remarks | Sale | 17,923 | $1.00 | 159,430 |
| Jan 6, 2026 | Sanjay Chandaofficer: Chief Development Officer | Sale | 5,956 | $1.01 | 75,823 |
| Jan 5, 2026 | Sanjay Chandaofficer: Chief Development Officer | Sale | 3,295 | $1.00 | 81,779 |
| Jan 6, 2026 | Stephen David Priorofficer: Chief Strategy Officer | Sale | 2,858 | $1.01 | 59,086 |
CongressHouse and Senate disclosures
Not reported.